Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions
Pharmacogenetic Testing
Interventions
DIAGNOSTIC_TEST

Panel-based pharmacogenetic genotyping

A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.

Trial Locations (1)

32610

UF Health at the University of Florida, Gainesville

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

University of Florida

OTHER